Streetbeat News

Equity Actions

TNON

Tenon Medical has successfully raised approximately $2.6 million through a Series A Preferred Stock offering. The company used part of the proceeds to retire $1.25 million in secured debt.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:06 pm

CHPT

ChargePoint Holdings (NYSE:CHPT) has been evaluated by 7 analysts over the last three months, showing a mix of bullish and indifferent sentiments. The average 12-month price target is now $2.77, significantly lower than the previous $6.58. The company's financial performance indicates challenges in revenue growth, net margin, ROE, ROA, and debt management, despite its leading position in the EV charging infrastructure market.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 1:00 pm

BCYC

Bicycle Therapeutics (NASDAQ:BCYC) received mixed analyst ratings with a shift towards bullish sentiment in the last quarter. The average 12-month price target is now $43.25, down from $49.00, indicating a 11.73% decrease. The company's financial performance shows strong revenue growth and net margin, but lags in ROA and has a prudent debt management strategy. Its main focus is on developing a novel class of medicines for oncology indications.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 1:00 pm

ENVB

Enveric Biosciences announced that its novel compounds, protected under its intellectual property portfolio, offer potential licensing opportunities and non-dilutive revenue streams. This development could enhance the company's financial stability and growth prospects without diluting existing shareholders' equity.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:00 pm

QDEL

QuidelOrtho's Board of Directors has terminated Douglas Bryant from his roles as President and CEO. Michael Iskra has been appointed as interim CEO, and Robert Bujarski as President.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:46 pm

BFH

Bread Financial has announced the approval of a new $30 million share repurchase program, signaling confidence in the company's financial health and future prospects.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:36 pm

VRSK

The board of directors at Verisk has approved an additional share repurchase authorization of $1.0 billion, indicating the company's confidence in its financial health and a commitment to returning value to shareholders.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:21 pm

BPTH

Bio-Path Holdings, Inc. has announced a 1-for-20 reverse stock split, which will be effective on February 23. This corporate action is typically undertaken to increase the market price of a company's shares, making them more appealing to investors and potentially in compliance with stock exchange listing requirements.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:16 pm

GRMN

On February 16, 2024, Garmin Ltd. (GRMN) announced that its Board of Directors has authorized a stock buyback program allowing the company to repurchase up to $300 million of its shares through December 26, 2026. The repurchases are subject to market and business conditions, legal requirements, and can be made in the open market or through privately negotiated transactions. The program does not commit Garmin to repurchase any specific number of shares and can be adjusted, paused, or terminated at any time.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:10 pm

NI

NiSource has increased its forecast for adjusted earnings per share (EPS) for fiscal year 2024 to $1.70 - $1.74, up from the previous range of $1.68 - $1.72. This adjustment is supported by a 5-year, $16 billion capital expenditure plan that is expected to result in an annual rate base growth of 8-10% and an annual non-GAAP net operating earnings per share (NOEPS) growth of 6-8% over the period from 2023 to 2028.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 11:34 am